Semaglutide Dosing: Weekly vs Monthly Schedules

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, semaglutide is not taken once a month for weight loss. Current clinical protocols use weekly subcutaneous injections at escalating doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg over four weeks. This weekly schedule is essential for therapeutic effect and safety monitoring.

Understanding why weekly dosing matters—and how individual factors like metabolism, baseline BMI, and genetic predispositions influence response—helps you have a more informed conversation with your provider about whether semaglutide and its dosing frequency align with your health goals.

Why Semaglutide Must Be Dosed Weekly, Not Monthly

Semaglutide's pharmacokinetics require weekly dosing to maintain therapeutic GLP-1 receptor activity. The drug has a 7-day half-life, meaning blood levels drop significantly after one week. Monthly dosing would result in subtherapeutic troughs and inconsistent appetite suppression, reducing efficacy for weight loss.

Clinical trials supporting semaglutide's weight-loss indication used strict weekly protocols. Deviating from this schedule—such as stretching to biweekly or monthly doses—has not been validated and may compromise safety monitoring and treatment outcomes.

Standard Semaglutide Titration Protocol and Individual Response Factors

The FDA-supported titration for compounded semaglutide begins at 0.25 mg weekly and increases by 0.25 mg each week until reaching the target maintenance dose of 2.4 mg. However, individual tolerability and metabolic factors influence how quickly this escalation proceeds and whether dose adjustments are needed.

Week	Standard Dose (mg)	Clinical Consideration
Week 1–4	0.25 mg	Initiation phase; monitors GI tolerance and appetite response
Week 5–8	0.5 mg	Early efficacy assessment; some patients remain here longer if tolerating well
Week 9–12	1.0 mg	Mid-range dose; metabolic biomarkers may shift; provider re-evaluation recommended
Week 13+	1.7–2.4 mg	Maintenance phase; individual response guides final target; genetic predisposition may influence plateau
Ongoing	Maintenance	Monthly provider check-ins support adherence and biomarker tracking

How Biomarkers Guide Dosing Decisions and Adherence Strategies

Baseline biomarkers—including fasting glucose, insulin, lipid panel, and GLP-1 receptor expression patterns—can inform whether slower or faster titration is appropriate for you. Patients with insulin resistance may tolerate higher doses earlier, while those with marginal baseline glucose control benefit from cautious escalation.

Regular biomarker re-evaluation at weeks 4, 8, and 12 helps your provider assess whether the current dose is producing metabolic benefit or if adjustment is warranted. This data-driven approach supports long-term adherence and reduces the likelihood of unexpected side effects or treatment plateau.

Safety Considerations and Who Should Discuss Weekly Semaglutide Dosing With Their Provider

Weekly semaglutide is not suitable for patients with personal or family history of medullary thyroid carcinoma, severe pancreatitis, or uncontrolled diabetic retinopathy. Pregnancy is a contraindication. GI side effects—nausea, vomiting, constipation—are dose-dependent and may require slower titration or temporary dose stabilization.

If you have renal impairment, hepatic disease, or take medications affecting GI motility, your provider should supervise dosing frequency and escalation timing. Weekly adherence requires reliable access, storage, and injection technique; discuss feasibility before initiating treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R pathways that may help provide context for how your body processes GLP-1 receptor signaling. These markers are distinct from weight-loss genes and should be interpreted alongside clinical biomarkers by your healthcare provider to support more personalized dosing conversations.

The test reveals predispositions in peptide genetic pathways—not exact medication response or optimal dose. For example, certain GLP1R variants correlate with baseline GLP-1 levels and may inform whether you benefit from standard versus extended titration schedules. This insight, combined with your baseline biomarkers, can guide more targeted protocol design.

Sharing your genetic predisposition report and biomarker trends with your provider enables a more precise discussion about whether weekly semaglutide aligns with your metabolic profile, optimal starting dose, and long-term adherence strategy. This precision-wellness approach reduces trial-and-error and supports sustainable outcomes.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.